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Abstract
Background: Niacin induces the release of vasodilating prostaglandins, for which receptors are present within the
pulmonary arterial circulation. We hypothesized that immediate-release niacin would reduce right ventricular systolic
pressure in patients with pulmonary hypertension in a randomized, double-blinded, single-dose provocation study.
Methods: We recruited inpatient subjects with a Doppler echocardiogram showing a peak tricuspid regurgitation (TR)
jet velocity of 2.7 m/s or greater, and who were free of known pulmonary vascular disease. Subjects were randomized
in a 1:2:2 ratio to receive a single dose of either placebo, niacin 100 mg or niacin 500 mg, respectively. TR jet velocities
were measured immediately before, and 1 hour post dose, corresponding to peak niacin absorption and prostaglandin
release. The primary endpoint was the change in mean TR jet velocity measured over ten successive cardiac cycles.
Results: The baseline mean estimated right ventricular systolic pressure (RVSP) for all 49 subjects (25 male) was 51.9 ±
12.1 mm Hg. The primary endpoint of mean change in TR jet velocity was 0.016 ± 0.065 m/s in the placebo group,
compared to −0.017 ± 0.065 m/s with niacin 100 mg, and −0.063 ± 0.038 m/s with niacin 500 mg (P = 0.63). The
change in maximum estimated RVSP across the three drug groups was 0.2 ± 1.6 mm Hg, −1.3 ± 1.8 mm Hg and −2.2 ±
1.2 mm Hg (P = 0.62). In exploratory pairwise analysis in the high-dose niacin group (500 mg), the reduction in mean
RVSP was from 50.9 ± 9.4 mm Hg to 48.7 ± 10.0 mm Hg (P = 0.09).
Conclusions: A single dose of immediate-release niacin (100 mg or 500 mg) had no significant effect on RVSP 1 hour
post administration. A nonsignificant dose-dependent trend for a modest reduction in RVSP, most notable in the
500 mg group, was noted.
(ISRCTN number 12353191, registered April 23, 2015).
Background
Pulmonary arterial hypertension (PAH) is a rare but in-
creasingly prevalent disease that is characterized by ab-
normal proliferation, remodeling, and contraction of
endothelial cells and smooth muscle cells within the pul-
monary artery in association with increased pulmonary
artery systolic pressure [1–3]. All approved treatments
used to treat PAH target an observable imbalance of vas-
cular tone through vasoconstricting (thromboxanes) and
vasodilating (prostaglandins) mediators [2, 4]. The po-
tent vasoconstrictor thromboxane A2 is countered by
the vasodilating prostacyclin (PGI2). In patients with
PAH, thromboxane A2 is elevated while prostacyclin is
diminished, leading to the high pulmonary pressures and
resistance.
Intravenous infusion of prostacyclin was the first drug
demonstrated to reduce pulmonary artery systolic pres-
sure and improve survival in patients with PAH [5].
Similarly, other vasodilators shown to be active in the
pulmonary arteries include calcium channel blockers,
endothelial receptor antagonists, nitric oxide, phospho-
diesterase (type 5) inhibitors, and synthetic prostacyclin
analogues. However, these treatment options are very
costly, difficult to administer, and accompanied by many
toxicities and complications [2, 6]. Niacin induces the
release of vasodilating prostaglandins, specifically lead-
ing to a several hundredfold increase in the concentra-
tion of prostaglandin D2 (PGD2) [7]. Through activation
of the prostaglandin D2 receptor, PGD2 mediates the
common side effect of cutaneous flushing seen during
oral administration. PGD2’s G protein-coupled receptor,
* Correspondence: Allen.Taylor@medstar.net
Cardiology Division, Medstar Heart and Vascular Institute at Medstar
Georgetown University Hospital and Medstar Washington Hospital Center,
3800 Reservoir Rd., NW, 5 PHC, Washington, DC, 20007, USA
TRIALS
© 2015 McNamara et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
McNamara et al. Trials  (2015) 16:530 
DOI 10.1186/s13063-015-1013-6
DP1, is also located on vascular muscle cells [8]. Thus,
given PAH’s vasoconstricting properties and niacin’s
vasodilating abilities, we hypothesized that administra-
tion of immediate-release niacin would reduce pulmon-
ary arterial pressure.
Methods
We conducted a randomized, placebo-controlled, double-
blinded, single-center pilot study on the effect of niacin on
pulmonary artery pressure. The study was ethically
approved by the Georgetown University Hospital
Institutional Review Board (GUH IRB) on October 5,
2011 (study number 2012–067). Taking part in the
study was entirely voluntary and informed consent
was obtained from every participant. A CONSORT
flow diagram and checklist are provided at the end of
the manuscript under the Additional files section
(Additional files 1 and 2). Echocardiographic tricuspid
regurgitation (TR) jet velocity was used as an accurate
noninvasive surrogate of pulmonary artery pressure
[9–11]. Participants were recruited by screening
inpatient echocardiogram logs at MedStar Georgetown
University Hospital (MGUH) for Doppler TR jet vel-
ocity greater than 2.7 meters/second (m/s). Patients
excluded from the study include the following: inability to
provide written, informed consent, known pulmonary
vascular disease, known intolerance to niacin or current
treatment with niacin, current treatment with a non-
steroidal anti-inflammatory drug (NSAID), known
liver disease (aspartate transaminase/alanine transaminase
(AST/ALT) >3 times the upper limit of normal), or
patients currently on ventilator support or using a bi-level
positive airway pressure (BiPAP) device.
Study drug
This was a single-dose provocation study evaluating niacin
(100 mg or 500 mg) versus placebo, in a 2:2:1 ratio. Niacin
was administered in the immediate-release, crystalline
form of nicotinic acid. The study drug was provided by a
research pharmacy with allocation concealed through
administration of niacin within identical capsules that
either contained placebo or niacin. The randomization
sequence was determined using a random number
generator and allocation concealed. Subjects were in the
nonfasting state prior to study drug administration, but
nothing by mouth (NPO) throughout the study.
Echocardiography
Doppler echocardiography (Philips IE33, Philips Elec-
tronics N.V., Amsterdam, The Netherlands) using a 3.5
mHz transducer was used to measure TR jet velocity im-
mediately pre/post administration of the study drug. In-
ferior vena cava (IVC) diameter and collapsibility was
assessed for estimation of right atrial pressure. After
baseline measurements were performed, the patient was
immediately administered a single dose of the study
medication. Sixty minutes later, corresponding to the usual
time of maximal niacin absorption and peak niacin-induced
cutaneous flushing, a second echocardiogram was done to
reassess TR jet velocity and IVC diameter. To eliminate
sonographer variability, the same sonographer performed
both the pre and post images. Echocardiography was
performed with the patient in the supine position. Doppler
recordings of TR jet velocity were acquired using apical,
lower left parasternal, and subcostal transducer positions.
The best view for TR jet velocity was determined in the
baseline echocardiogram. This optimal view of TR jet
velocity was used for both the pre and post imaging. The
TR jet velocity measurements were determined from the
average of ten consecutive cardiac cycles when possible.
Otherwise, multiple frames of peaks were captured and the
most accurate envelopes were chosen for measurement.
TR jet velocities were measured by two independent inter-
preters unaware of study drug assignment.
Endpoints and statistical analysis
The primary endpoint was the change in mean TR jet vel-
ocity measured in meters/second (m/s). The secondary
endpoint was the change in maximum TR jet velocity.
Between-group differences in baseline and endpoint vari-
ables were performed using analysis of variance (ANOVA)
between the three randomization groups. Dose compari-
sons were adjusted for multiple endpoint testing using a
Bonferroni correction. Right ventricular systolic pressure
(RVSP) was estimated via the modified Bernoulli equation.
A P value of <0.05 was considered statistically significant.
Prespecified endpoints were examined using two-tailed
hypothesis testing. Exploratory endpoints were examined
using one-tailed testing. Statistics were performed using
SPSS (version 16.0; SPSS Inc., Chicago, IL, USA).
Results
A total of 126 patients were approached for consent be-
tween June 2013 and April 2014. A total of 50 patients
were included in the study. One patient was later ex-
cluded from analysis due to a discrepancy on the qualify-
ing echocardiogram. Ten patients were randomized to
receive placebo, 19 patients received 100 mg of niacin,
and 20 patients received 500 mg of niacin. All enrolled
patients completed the study. Baseline characteristics of
each group are described in Table 1. The mean age was
68 ± 16, and 25 were men (51 %). None had known
pulmonary vascular disease. Six patients (12.2 %) had a
history of chronic obstructive pulmonary disease. Baseline
TR jet velocity was 2.97 ± 0.38 m/s, and mean estimated
pulmonary artery systolic pressure was 45.9 ± 9.5 mm Hg.
There were no significant differences in baseline variables
between study groups.
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The baseline mean estimated RVSP for all 49 subjects
(25 male) was 51.9 ± 12.1 m/s. The primary endpoint of
mean change in TR jet velocity was 0.016 ± 0.065 m/s in
the placebo group, compared to −0.017 ± 0.065 m/s with
niacin 100 mg, and −0.063 ± 0.038 m/s with niacin
500 mg (P = 0.63). The change in maximum estimated
RVSP across the three drug groups was 0.2 ± 1.6 mm
Hg, −1.3 ± 1.8 mm Hg and −2.2 ± 1.2 mm Hg (P =
0.62). In exploratory pairwise analysis in the high-dose
niacin group (500 mg), the reduction in mean RVSP was
from 50.9 ± 9.4 mm Hg to 48.7 ± 10.0 mm Hg (P = 0.09).
Exploratory pairwise analysis in the other two groups
yielded nonsignificant P values. There were no differences
observed within strata of baseline RVSP (above or below
median RVSP) or for age (Fig. 1).
Discussion
We hypothesized that niacin-mediated prostaglandin re-
lease might lead to measurable acute effects on right
ventricular systolic pressure in patients with pulmonary
hypertension. In this pilot study, we have shown that
major changes in RVSP were not observed after single-
dose provocation with 100 mg or 500 mg of niacin.
However, with a dose–response difference, our data are
consistent with a possible small reduction in RVSP at
the 500 mg dose. These data provide insights for future
studies on the topic, in particular dosing, effects of dos-
ing at 1 hour, and data for sample size determinations.
Long known is niacin’s principle side effect of vaso-
dilatory flushing, exhibited after oral ingestion of large
doses or immediate-release niacin. The physiological
mechanism of flushing relates to an abnormally large
concentration of prostaglandins released upon niacin ab-
sorption, predominantly PGD2 [7]. Ingested niacin binds
to G protein-coupled receptor 109A (GPR109A), trigger-
ing a signal cascade leading to PGD2 formation and
release [12]. Subsequent vasodilation only occurs after
PGD2 binds to its receptor DP1, located on vascular
muscle cells [8, 13]. This knowledge led to our hypoth-
esis that pulmonary artery vasodilation may be a physio-
logical correlate of niacin-induced prostaglandin release.
Niacin has not previously been investigated for its ef-
fects on pulmonary artery pressure. Indeed, new simple
and low-cost treatments for PAH are needed. Low levels
of vasodilating prostaglandins and high levels of vaso-
constricting thromboxanes result in the high pulmonary
pressures and resistance evident in patients with PAH
[2, 4]. Long-term, intravenous administration of prosta-
cyclin (PGI2) has seen the most success in treating this
imbalance, providing symptomatic alleviation, hemo-
dynamic improvement, and prolonged survival in pa-
tients [5, 6]. It has also been shown to significantly
reduce echocardiographic measurements of maximum
TR jet velocity after 12 weeks of therapy [14]. However,
complications are common and new treatment options
using synthetic prostacyclin analogues and other prosta-
glandins are continuously being explored. A particular
limitation of such treatments is their expense.
Several opportunities exist for applying these results to
future studies. First, without appropriate animal models
or prior experience to guide us, we selected doses of
100 mg and 500 mg of niacin based largely on the max-
imal initial doses of immediate-release niacin that are
tolerable. Based upon pharmacokinetic bioavailability,
we estimated that 1 hour post administration would be
the time of exposure to maximal PGD2 levels correlating
to the typical period of cutaneous flushing. This study
explored niacin’s (putatively via PGD2) ability to quanti-
tatively reduce pulmonary arterial pressure assessed
using TR jet velocity. Although we found no overall ef-
fect, several potential opportunities for future research
emerged. First, our data suggests a positive trend with
larger reductions of pulmonary arterial pressure at the
highest dose (500 mg) of niacin. Second, our data are
compatible with a small reduction in RVSP at the
500 mg dose, although we caution that this is a sub-
group endpoint and found within exploratory statistical
methods that require further hypothesis generation and
testing. Our study supports the feasibility and safety of
administration of niacin as a pulmonary vasodilator
among patients with overall mild to moderate pulmon-
ary hypertension. Given the indirect nature of assess-
ment of RVSP using TR jet velocity, future studies
should utilize more direct techniques such as pulmonary
artery catheterization that, although invasive, would be
more definitive and aid in the determination of the time
course of effect. For example, intravenous prostacyclin
in acute administration results in little change in pul-
monary artery systolic pressure due to an offsetting
effect of increased cardiac output in the setting of pul-
monary artery vasodilation [14]. As niacin may stimulate
a number of offsetting hemodynamic variables such as
Table 1 Baseline characteristics in patients assigned to placebo,







Age (years) 69 ± 18.9 69 ± 15.5 67 ± 16.6
Male (N, %) 4 (40) 12 (63) 9 (45)
Hypertension (N, %) 6 (60) 12 (63) 16 (80)
Diabetes mellitus (N, %) 3 (30) 5 (26) 4 (20)
Hyperlipidemia (N, %) 1 (10) 3 (16) 4 (20)
COPD (N, %) 1 (10) 3 (16) 2 (10)
Smoker (N, %) 2 (20) 5 (26) 9 (45)
Left ventricular ejection
fraction
56 ± 11.7 % 51 ± 13.3 % 56 ± 5.8 %
COPD chronic obstructive pulmonary disease
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increased cardiac output in a setting of reduced pulmon-
ary vascular resistance yielding no net effect on RVSP,
the hypothesis that niacin induces pulmonary artery
vasodilation may not be inconsistent with our initial
findings.
Limitations
We utilized TR jet velocity as a surrogate to pulmonary
pressure given its noninvasive nature and the pilot study
approach. Although accurate, the pressures derived are
dependent on a number of assumptions and technical
optimization. Although we attempted to eliminate inter-
est variability through consistency in the sonographer
and insonation views, a more direct approach utilizing
pulmonary artery catheterization would be advised for
more definitive evaluation. There are many different eti-
ologies underlying PAH. Additionally, not all forms of
PAH will respond equally to vasodilators. This intro-
duces the possibility of a heterogeneous study popula-
tion. We selected a niacin dose for this study based
upon tolerance for initial dosing of the drug. If poten-
tial favorable effects on pulmonary artery pressure are
shown through future studies, dose optimization during
titration and sustained administration would be necessary.
Our study was designed to detect a small change in TR jet
velocity, although the standard deviation was larger
than anticipated. Our data should aid future investiga-
tors in sample size determinations. Lastly, we empir-
ically elected to assess the change in TR jet velocity
after 60 minutes, based upon the time course of clinical
flushing caused by increased circulating levels of PGD2.
However, absorption rates between patients may vary, and
indeed patients differed in the time when maximum flush-
ing occurred, most prior to the second echocardiogram
and a few after.
Conclusions
Niacin, via stimulation of PGD2 release, may favorably
reduce pulmonary artery pressure in patients with mild
to moderate pulmonary artery hypertension. However,
this pilot study did not meet its primary and secondary
endpoints of change in mean and maximum TR jet vel-
ocity, while demonstrating a trend for dose response
and possible reduction of RVSP at the 500 mg dose.
Future studies utilizing direct measurements of pul-
monary artery pressure and repeat niacin dosing are
warranted.
Fig. 1 Mean and maximum change in RVSP in mm Hg in all study groups. Mean change in estimated right ventricular systolic pressure (RVSP) in
mm Hg for placebo, niacin 100 mg, and niacin 500 mg measured 1 hour after medication administration. Data displayed are for the changes
observed in average RVSP (blue), and in maximum RVSP (green) observed in up to ten consecutive Doppler measurements
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